## UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.
Petitioner

v.

QUALICAPS CO. LTD.
Patent Owner

Case IPR2017-00203 Patent No. 6,649,180

PETITIONER MYLAN PHARMACEUTICALS INC.'S REQUEST FOR ORAL ARGUMENT



## **EXHIBIT LIST**

Exhibit No.	Description
1001	United States Patent No. 6,649,180
1002	Complaint, Warner Chilcott (US), LLC et al. v. Mylan Pharmaceuticals, Inc., et al., Case No. 2:15-cv-01740-JRG-RSP (E.D. Texas)
1003	Proof of Service of Complaint, Case No. 2:15-cv-01740-JRG-RSP (E.D. Texas)
1004	United States Patent No. 5,756,123 ("Yamamoto")
1005	The Japanese Pharmacopeia (The Society of Japanese Pharmacopeia, 13th ed. 1996) ("Japanese Pharmacopeia")
1006	United States Patent No. 3,493,407 ("Greminger")
1007	21 C.F.R. § 172.874 (1998)
1008	National Formulary (American Pharmaceutical Association, 12th ed. 1965)
1009	Handbook of Pharmaceutical Excipients (1986)
1010	File History of United States Patent No. 6,649,180
1011	Expert Declaration of Arthur H. Kibbe
1012	Shin-Etsu Chemical Co., Ltd. PHARMACOAT Technical Information Shin-Etsu Chemical Co., Ltd. TC-5 Technical Information
1013	Chichester, C.O., E.M. Mrak, and G.F. Stewart, "Utilization of Synthetic Gums in the Food Industry," <u>Advances in Food Research, Volume 12, Technical Center, General Foods</u>



	Corporation, Tarrytown, N.Y., 1963.
1014	Deposition Transcript of Jason T. McConville, Ph.D., Case No. 2:15-cv-1471-JRG-RSP (E.D. Tex.), July 8, 2016
1015	Declaration Of Mr. Jonathan D. Olinger In Support Of Petitioner's Unopposed Motion For <i>Pro Hac Vice</i> Admission Under 37 C.F.R. § 42.10(C)
1016	United States Patent No. 5,756,123 ("Yamamoto") (Served but not filed, June 14, 2017)
1017	The Japanese Pharmacopeia (The Society of Japanese Pharmacopeia, 13th ed. 1996) ("Japanese Pharmacopeia") (Served but not filed, June 14, 2017)
1018	21 C.F.R. § 172.874 (1998) (Served but not filed, June 14, 2017)
1019	National Formulary (American Pharmaceutical Association, 12th ed. 1965) (Served but not filed, June 14, 2017)
1020	Handbook of Pharmaceutical Excipients (1986) (Served but not filed, August 11, 2017)
1021	Email exchange between counsel July 25, 2017 (Served but not filed, August 11, 2017)
1022	Email exchange between counsel August 4, 2017 (Served but not filed, August 11, 2017)
1023	Email exchange between counsel August 10, 2017 (Served but not filed, August 11, 2017)
1024	Mylan Pharmaceuticals Inc., Mylan Laboratories Limited, and Mylan Inc.'s Amended Notice Of Videotaped Deposition Of Representative(s) Of Qualicaps Co., Ltd. Pursuant To Federal Rule Of Civil Procedure 30(B)(6) (Served but not filed, August 11, 2017)
1025	Email exchange between counsel March 21, 2017 (Served but not filed, August 11, 2017)
1026	Email exchange between counsel April 25, 2017 (Served but not filed, August 11, 2017)



1027	Amended Docket Control Order, Warner Chilcott (US), LLC v. Teva Pharmaceuticals USA, Inc., No. 2:15-cv-1471 (E.D. Tex. May 19, 2017), ECF No. 165 (Served but not filed, August 11, 2017)
1028	Deposition Transcript of Jason T. McConville, Ph.D., August 17, 2017
1029	Reply Expert Declaration of Arthur H. Kibbe



Pursuant to 37 C.F.R. § 42.70(a) and the Board's Amended Scheduling

Order (Paper No. 42), Petitioner Mylan Pharmaceuticals Inc. respectfully submits

this Request for Oral Argument. As set forth in the Amended Scheduling Order,

the Board has scheduled oral argument for January 25, 2018. Paper No. 42, at 1.

Petitioner specifies the following issues to be argued:

• Claims 1 and 4 of the '180 Patent are not patentable as obvious in

view of Ex. 1004 United States Patent No. 5,756,123 ("Yamamoto") in

combination with Ex. 1005 The Japanese Pharmacopeia (The Society of Japanese

Pharmacopeia, 13th ed. 1996) ("Japanese Pharmacopeia");

• Any other issues identified by Patent Owner for oral argument or any

other issues raised in papers yet to be filed; and

Any other issues the Board deems necessary for issuing a final written

decision.

Petitioner requests permission to use audio/visual equipment at the oral

argument, including a projector and screen for displaying evidence or

demonstrative exhibits.

Respectfully submitted,

Dated: December 6, 2017

Respectfully submitted,

By: s/Mitchell G. Stockwell

Mitchell G. Stockwell

Registration No. 39,389

Lead Counsel for Petitioner



# DOCKET

## Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

### **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

#### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

#### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

